Treatments with Vitamin K antagonists or novel oral anticoagulants (NOACs) can dramatically lower the risk of ischemic strokes in the presence of AFib. Non-adherence can expose the patients to an increased stroke risk. This is especially true for NOACs, due to their short half-life. Patients ...
Current treatments for Graves’ hyperthyroidism (GH) and Graves’ orbitopathy (GO) are ineffective. Researchers assessed the preclinical in vitro efficacy of SYD-5115 (Byondis BV), a novel low-molecular-weight thyrotropin receptor (TSH-R) antagonist. The compound comprises ...
Our goals are to protect and restore your heart's health by offering comprehensive cardiovascular programs and treatments for all types of heart and vascular conditions. Our multidisciplinary team of experts uses the latest technology, conducts cutting-edge research, and participates in the latest clini...
dominant-negative form and a constitutive-active form of STAT3, respectively, demonstrated the necessity and sufficiency of astrocytic STAT3 in the maintenance of neuropathic pain following peripheral nerve injury, a debilitating chronic pain state in which currently available treatments are frequently ...
up to four-and-a-half hours in some people) after symptoms begin. Mechanical removal of the clot (also called endovascular therapy) may be safe for some people up to 24 hours after stroke symptoms start. However, not all people experiencing a stroke have rapid access to...
companies. Headquartered in Ingelheim, Germany, the company operates globally with 146 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments forhumanand veterinary ...
Of the rest, 98.3% of the people who had AFib were correctly identified as having it. And 99.6% of the time, the app also correctly identified people who didn’t have AFib.” “For the irregular rhythm notification feature, the app wasn’t as accurate. The FDA said it reviewed data ...
However, the battle between the old and new paradigms of drug therapy continues to rage for different pharmacological treatments, and perhaps is most evident in the area of oral anticoagulants. From 1954–2009, warfarin was the only approved oral anticoagulant on the market with a long track ...
"Minimizing risk and making potentially effective treatments more broadly available is critical to providing therapy to the largest number of patients," says Dr. Kapa. It is estimated that 12.1 million people in the U.S. will be diagnosed with AFib by 2030—more than double the number in 2010...
"Based on our study, digoxin should be avoided in patients with AFib, particularly if symptoms can be alleviated with other treatments," said Renato Lopes, MD, PhD, professor of medicine in the division of cardiology at Duke University Medical Center and lead author of the study. "We showed...